None of the 29 investors followed here reported a position in BIO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BIO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Allison SchwartzDirector | — | 320 | — |
| Sep 3, 2026 | Evran SedatOfficer | — | 1.9K | — |
| Sep 3, 2026 | Enloe Courtney CGeneral Counsel | — | 1.5K | — |
| Sep 3, 2026 | Barry JamesOfficer | — | 2.1K | — |
| Sep 3, 2026 | Engelhardt Eva AnetteOfficer | — | 2.2K | — |
| Sep 3, 2026 | Mehta RajatOfficer | — | 1.8K | — |
| Sep 3, 2026 | Divincenzo Jonathan PPresident | — | 1.7K | — |
| Sep 3, 2026 | Lakkaraju Roop KalyanChief Financial Officer | — | 2.9K | — |
| Sep 3, 2026 | Schwartz Norman DChief Executive Officer | — | 7.6K | — |
| Aug 31, 2026 | Allison SchwartzDirector | — | 117 | — |
| Aug 31, 2026 | Barry JamesOfficer | — | 425 | — |
| Aug 31, 2026 | Schwartz Norman DChief Executive Officer | — | 5.1K | — |
| Jul 23, 2026 | Engelhardt Eva AnetteOfficer | — | 246 | — |
| May 10, 2026 | Engelhardt Eva AnetteOfficer | Sale at price 246.54 per share. | 550 | $135.60K |
| Apr 23, 2026 | Enloe Courtney CGeneral Counsel | — | 186 | — |
| Apr 23, 2026 | Lakkaraju Roop KalyanChief Financial Officer | — | 1.1K | — |
| Apr 20, 2026 | Pei Melinda LitherlandDirector | — | 407 | — |
| Apr 20, 2026 | Pinkston Arnold ADirector | — | 407 | — |
| Apr 20, 2026 | Edwards Jeffrey LDirector | — | 407 | — |
| Apr 20, 2026 | Hinckley Gregory KDirector | — | 407 | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.1 | -5.2 | 0.1 | 0.5 | 11.6 | -6.0 | 10.9 | 18.6 | -2.2 | -4.6 | +19.0% | ||
| 2025 | 9.9 | -26.5 | -8.1 | 0.2 | -7.0 | 6.3 | 0.3 | 23.1 | -5.9 | 14.0 | 1.7 | -6.7 | −7.8% |
| 2024 | -0.6 | 1.6 | 6.1 | -22.0 | 6.3 | -4.8 | 23.9 | -0.3 | -0.8 | 7.1 | -4.9 | -3.5 | +1.7% |
| 2023 | 11.2 | 2.2 | 0.2 | -5.9 | -17.2 | 1.5 | 6.9 | -1.3 | -10.4 | -23.2 | 10.8 | 5.9 | −23.2% |
| 2022 | -20.6 | 4.4 | -10.0 | -9.1 | 5.0 | -8.0 | 13.8 | -13.9 | -14.0 | -15.7 | 17.9 | 1.4 | −44.3% |
| 2021 | -1.6 | 1.9 | -2.3 | 10.3 | -4.4 | 7.0 | 14.8 | 8.8 | -7.3 | 6.5 | -5.2 | 0.3 | +29.6% |
| 2020 | -2.5 | -2.5 | -0.4 | 25.5 | 11.6 | -8.1 | 16.3 | -3.1 | 1.4 | 13.8 | -8.2 | 8.3 | +57.5% |
| 2019 | 7.6 | 8.4 | 12.8 | -1.6 | -4.7 | 8.9 | 0.7 | 7.2 | -1.5 | -0.3 | 11.4 | 0.2 | +59.3% |
| 2018 | 8.3 | 4.5 | -7.4 | 1.5 | 13.2 | 0.5 | 6.3 | 6.1 | -3.8 | -12.8 | 0.6 | -15.4 | −2.7% |
| 2017 | 4.3 | 2.4 | 2.4 | 9.5 | 2.4 | 1.3 | 4.1 | -7.6 | 2.0 | -1.1 | 23.4 | -12.0 | +30.9% |
| 2016 | -8.0 | 5.5 | 1.5 | 3.8 | 4.9 | -3.9 | 1.4 | 2.6 | 10.1 | -3.5 | 9.8 | 5.1 | +31.5% |
| 2015 | -5.1 | 11.1 | 6.3 | -0.5 | 7.4 | 4.3 | 0.1 | -7.6 | -3.6 | 3.8 | 0.2 | -0.8 | +15.0% |
| 2014 | 2.8 | 2.0 | -1.2 | -3.8 | -2.0 | -0.8 | -3.9 | 4.6 | -5.7 | -0.5 | 5.3 | 1.5 | −2.5% |
| 2013 | 8.3 | 8.3 | 2.3 | -5.0 | -5.1 | -1.3 | 8.7 | -6.5 | 3.1 | 5.1 | -0.7 | 0.8 | +17.7% |
| 2012 | 5.7 | 0.4 | 1.7 | 4.1 | -7.8 | 0.4 | -3.8 | 4.3 | 6.3 | -5.0 | 3.1 | 0.5 | +9.4% |
| 2011 | 4.8 | 4.8 | 5.2 | 4.1 | -0.6 | -4.1 | -8.7 | -7.9 | -9.5 | 9.7 | -5.3 | 1.8 | −7.5% |
| 2010 | -3.4 | 0.2 | 10.8 | 7.9 | -16.2 | -7.6 | 2.7 | -7.1 | 9.7 | 0.1 | 3.0 | 11.2 | +7.7% |
| 2009 | -15.6 | -12.3 | 18.3 | 5.8 | 6.8 | 1.4 | 2.6 | 11.4 | 6.5 | -2.7 | 8.2 | -0.2 | +28.1% |
| 2008 | -8.5 | -0.4 | -5.8 | -6.3 | 7.4 | -9.6 | 10.1 | 20.8 | -7.9 | -13.9 | -13.1 | 1.6 | −27.3% |
| 2007 | 4.3 | -17.6 | -1.5 | 1.3 | 5.6 | 1.2 | -1.9 | 13.7 | 7.3 | 6.7 | 4.5 | 2.7 | +25.6% |
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Buy / hold / sell counts
No recent headlines.